NasdaqGS:TEMLife Sciences
Tempus AI (TEM) Valuation Check As Q1 2026 Growth And New Pharma Collaborations Refocus Attention
Tempus AI (TEM) is back in focus after reporting 36.1% year-over-year revenue growth in Q1 2026 and lifting its full-year revenue guidance, supported by oncology diagnostics, data applications, and new pharmaceutical collaborations.
See our latest analysis for Tempus AI.
Despite the strong Q1 update and new collaborations in oncology and Alzheimer’s care, Tempus AI’s short-term sentiment has been weak. The company reported a 1-day share price return of 7.61% and a year-to-date share price...